Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 4:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: esomeprazole (PPI) Clear all
Withdrawn Phase 4 Interventional

Total Antioxidant Effects of Esomeprazole in Dyspeptic Patients Receiving Non-steroidal Anti-inflammatory Drugs

NCT00443963
View directory record Official record
Conditions
Dyspepsia
Interventions
Esomeprazole Magnesium
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Oct 16, 2026, 4:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.

NCT00942175
View directory record Official record
Conditions
Healthy
Interventions
Clopidogrel, Clopidogrel and Lansoprazole, Clopidogrel and Dexlansoprazole, Clopidogrel and Omeprazole, Clopidogrel and Esomeprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 16, 2026, 4:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Which Supraesophageal Reflux Symptoms Reliably Respond to Proton-Pump-Inhibitor (PPI) Therapy

NCT00170001
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Nexium, Sugar Pill
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 15, 2011 · Synced Oct 16, 2026, 4:44 PM EDT
Completed Phase 2 Interventional Results available

A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)

NCT02637557
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
IW-3718, Matching Placebo, PPI
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
62
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 16, 2026, 4:44 PM EDT
Completed Phase 4 Interventional

The Effects of Nexium on the Side Effects Associated With a Colonoscopy Prep

NCT00225238
View directory record Official record
Conditions
Nausea, Vomiting, Abdominal Pain
Interventions
esomeprazole (PPI)
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 16, 2026, 4:44 PM EDT
Completed Not applicable Interventional

The Effect of Prolonged Multimodal Analgesic Regimen on Post Hospital Discharge Opioid Use and Pain Control After Primary Total Knee Arthroplasty

NCT04003350
View directory record Official record
Conditions
Osteo Arthritis Knee
Interventions
Oxycodone, Tramadol, Tylenol, Meloxicam, Gabapentin, Metaxalone, Esomeprazole 20mg
Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Oct 16, 2026, 4:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Different Formulations of LY3410738 in Healthy Adult Participants

NCT06181084
View directory record Official record
Conditions
Healthy
Interventions
LY3410738, Esomeprazole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 16, 2026, 4:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Diagnosis of Acid Reflux Disease Using Novel Imaging: A Prospective Study

NCT02081404
View directory record Official record
Conditions
Non-erosive Reflux Disease
Interventions
Esomeprazole, Placebo
Drug
Lead sponsor
Midwest Biomedical Research
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2020
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 16, 2026, 4:44 PM EDT
Completed Phase 4 Interventional Results available

Pilot Study To Investigate The Association Between Acid Control And Heartburn Symptoms After Proton Pump Inhibitor Treatment

NCT02708355
View directory record Official record
Conditions
Heartburn
Interventions
Esomeprazole 20 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
22 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 16, 2026, 4:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of Food and Esomeprazole on the Pharmacokinetics of Crizotinib in a Coated Microsphere Formulation.

NCT03137134
View directory record Official record
Conditions
Healthy
Interventions
Crizotinib, Esomeprazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 31, 2017 · Synced Oct 16, 2026, 4:44 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Confocal Endomicroscopy for Non-Erosive Reflux Disease Detection

NCT02788591
View directory record Official record
Conditions
Non-erosive Reflux Disease, Gastroesophageal Reflux
Interventions
Proton Pump Inhibitor (PPI) Therapy, Sucralfate
Drug
Lead sponsor
LCMC Health
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
2
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 9, 2022 · Synced Oct 16, 2026, 4:44 PM EDT
Completed Phase 2 Interventional Results available

Effect of Proton Pump Inhibitors on CF Pulmonary Exacerbations

NCT01983774
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Esomeprazole, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Oct 16, 2026, 4:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults

NCT06793943
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Zasocitinib, COC, Metformin, Digoxin, Esomeprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 16, 2026, 4:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil

NCT00963027
View directory record Official record
Conditions
Hypertension, Pulmonary, Pulmonary Arterial Hypertension
Interventions
Treprostinil diethanolamine, Esomeprazole
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2010 · Synced Oct 16, 2026, 4:44 PM EDT
Not listed Phase 1 Interventional

The Effect of Nexium on Transmucosal Esophageal Leak

NCT00216788
View directory record Official record
Conditions
Reflux, Esophagitis, Barrett's Esophagus
Interventions
Esomeprazole (Nexium) 40 mg/day
Drug
Lead sponsor
Main Line Health
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Wynnewood, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2010 · Synced Oct 16, 2026, 4:44 PM EDT
Completed Phase 4 Interventional

Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERD

NCT00410592
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Esomeprazole 40mg, Pantoprazole 40mg, Lansoprazole 30mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 69 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
Anaheim, California • Orange, California • San Diego, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2009 · Synced Oct 16, 2026, 4:44 PM EDT
Terminated Not applicable Interventional Results available

COPD Patients Diagnosed With GERD,COPD Exacerbations After Treatment With High Dose PPI

NCT00523367
View directory record Official record
Conditions
Gastroesophageal Reflux, Chronic Obstructive Pulmonary Disease
Interventions
24 hour pH testing
Procedure
Lead sponsor
University of Florida
Other
Eligibility
40 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 16, 2026, 4:44 PM EDT
Completed Phase 1 Interventional

A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer

NCT00849329
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
lapatinib, lapatinib plus esomeprazole
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 16, 2026, 4:44 PM EDT
Not listed Phase 2Phase 3 Interventional

Effect of Esomeprazole 40 mg.Daily for 7 Days on Acid Reflux and Related Arousals During Sleep in Patients With GERD

NCT01089959
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
esomeprazole
Drug
Lead sponsor
Southern Arizona VA Health Care System
Federal
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 19, 2010 · Synced Oct 16, 2026, 4:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Trial to Evaluate the Effect of the Proton Pump Inhibitor Esomeprazole on the Single-dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants

NCT03849690
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-906, Esomeprazole
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Oct 16, 2026, 4:44 PM EDT
Completed Phase 4 Interventional Results available

Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors

NCT03094416
View directory record Official record
Conditions
Hypothyroidism;Postablative
Interventions
levothyroxine sodium capsule, Proton pump inhibitor (PPI), Levothyroxine Sodium (LT4) Tablets
Drug
Lead sponsor
IBSA Institut Biochimique SA
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
La Jolla, California • Ventura, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 16, 2026, 4:44 PM EDT
Completed Phase 3 Interventional Results available

Study of Acid Reflux in Asthma

NCT00069823
View directory record Official record
Conditions
Asthma, Lung Diseases, Lung Diseases, Obstructive
Interventions
Esomeprazole, Placebo proton pump inhibitor
Drug
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
20
States / cities
Birmingham, Alabama • San Diego, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2012 · Synced Oct 16, 2026, 4:44 PM EDT
Completed Phase 4 Interventional Results available

Implementation of PPI Medication PGX Testing

NCT02794844
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Genotype Guided PPI Dosing
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
2 Years to 17 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 21, 2018 · Synced Oct 16, 2026, 4:44 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)

NCT00978016
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
arbaclofen placarbil-Cohort 1, Placebo-Cohort 5, arbaclofen placarbil-Cohort 2, arbaclofen placarbil-Cohort 3, arbaclofen placarbil-Cohort 4, PPI
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
62
States / cities
Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 16, 2026, 4:44 PM EDT